Tom A. Brieva, Ph.D.Vice President, Process Development at Tmunity Therapeutics
Tom Brieva has played a process development role in the commercialization of cell-based pharmaceuticals since joining industry in 2004, first at Celgene/BMS and now at Tmunity Therapeutics. His accomplishments include the development of robust, reproducible, economically viable cell manufacturing processes and the implementation of them to the in-house generation of GMP grade product from clinical through commercial stages. Tom has led process development for a variety of autologous and expanded allogeneic cell-based products that originated either internally or from external industrial or academic partners. These products range from expanded umbilical cord blood stem cells to placenta-derived MSC-like cells to CAR T cells as well as gene delivery vectors.